Related Experiment Video

Updated: Jul 5, 2026

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach
05:30

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach

Published on: August 8, 2025

Management of cutaneous hemangiomas in pediatric patients

Maria Letizia Musumeci1, Karina Schlecht, Rosario Perrotta

  • 1Department of Dermatology, University of Catania, Italy.

Cutis
|May 22, 2008
PubMed

Insights

Cutaneous hemangiomas (CHs), common childhood vascular tumors, often resolve spontaneously. Treatment is reserved for CHs causing functional issues, significant size, or complications like ulceration, with various therapeutic options available.

Area of Science:

  • Pediatric Dermatology
  • Vascular Biology
  • Oncology

Background:

  • Cutaneous hemangiomas (CHs) are prevalent benign vascular tumors in infants.
  • CHs exhibit a predictable growth and involution pattern, typically resolving by age 10.
  • Intervention is necessary for CHs with functional risks, large size, or complications.

Purpose of the Study:

  • To provide a comprehensive overview of treatment strategies for cutaneous hemangiomas.
  • To discuss first-line, second-line, and third-line therapeutic options.
  • To review emerging and alternative therapies for CHs, including ulcerated forms.

Main Methods:

  • Literature review of established and experimental treatments for CHs.
  • Categorization of therapies based on treatment lines and specific indications.
  • Inclusion of procedural and prospective agents.

Main Results:

  • Corticosteroids are the primary treatment for problematic CHs.
  • Second-line options include interferon, laser, and surgery.
  • Third-line and other therapies encompass cytotoxins, embolization, compression, cryosurgery, radiotherapy, and novel agents like OXi4503 and cidofovir.

Conclusions:

  • A tiered approach to CH management is essential.
  • Treatment selection depends on CH characteristics and complications.
  • Ongoing research explores new agents for refractory or complex cases.

More Related Videos

A Patient-Derived Xenograft Model for Venous Malformation06:51

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

Related Concept Videos

Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...